Form 4: Theodore R. Samuels II Reports Acquisition of Deferred Share Units in Bristol-Myers Squibb Co.

Director Theodore R. Samuels II reports acquisition of deferred share units in Bristol-Myers Squibb Co.

Summary

• Theodore R. Samuels II, a director of Bristol-Myers Squibb Co. (BMY), filed a Form 4 on April 02, 2024, reporting changes in beneficial ownership.
• On March 31, 2024, Samuels acquired 921.999 deferred share units, each convertible into one share of common stock upon settlement.
• The price per deferred share unit was $54.23.
• Following the transaction, Samuels beneficially owns 47,858.919 deferred share units directly.
• The deferred share units become settleable when Samuels ceases to be a director or at a future date previously specified.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it is a standard regulatory filing detailing a transaction by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency.

Positives

• The acquisition of deferred share units indicates a continued investment and alignment of interests between the director and the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the director's investment in the company.

Key Dates